Milameline

Milameline

Milameline is a pharmacological agent that was developed for the treatment of Alzheimer's disease and other cognitive disorders. It is classified as a muscarinic receptor agonist, which means it works by stimulating the muscarinic acetylcholine receptors in the brain.

Pharmacology

Milameline is a non-selective muscarinic receptor agonist. It has a high affinity for all five subtypes of muscarinic receptors (M1-M5), but it has a slightly higher affinity for the M1 and M4 subtypes. The activation of these receptors by milameline leads to an increase in the release of acetylcholine, a neurotransmitter that plays a crucial role in memory and learning.

Clinical Trials

Milameline has been tested in several clinical trials for the treatment of Alzheimer's disease. However, the results have been mixed. Some studies have shown that milameline can improve cognitive function in patients with mild to moderate Alzheimer's disease, while others have found no significant benefit.

Side Effects

The most common side effects of milameline are gastrointestinal disturbances, such as nausea and diarrhea. Other side effects can include dizziness, headache, and increased heart rate.

Development and Marketing

Milameline was developed by the pharmaceutical company Eli Lilly and Company. However, the drug was never marketed due to concerns about its side effect profile and lack of efficacy in clinical trials.

See Also

• Muscarinic acetylcholine receptor
• Alzheimer's disease
• Cognitive disorders
• Clinical trials